Search
Quanterix Corp
QTRXAdd to Watchlist
4.330USD
-0.010-0.23%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
203.77MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.23%
5 Days
+0.23%
1 Month
+13.95%
6 Months
-32.66%
Year to Date
-31.92%
1 Year
-37.97%
Key Figures
4.380Open
4.440High
456.29KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.97%Turnover Ratio
4.340Prev. Close
4.220Low
1.42MTurnover
LossP/E Static
0.72P/B
0.00%Div Yield TTM
-27.30%ROA
8.77052wk High
0.53Volume Ratio
-38.53MNet Profit
47.06MShares
-2.3568EPS TTM
1.37Beta
-34.81%ROE
3.36052wk Low
5.07%Amplitude
42.75%Gross Margin
203.77MMarket Cap
2.97Reward/Risk
4.79%Risk Rate
TradingKey Stock Score of Quanterix Corp
Currency: USD Updated: 2026-07-02Key Insights
Quanterix Corp's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 100 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 4.33.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Quanterix Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Quanterix Corp Highlights
StrengthsRisks
Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 138.90M.
Overvalued
The company’s latest PE is -1.84, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 42.63M shares, decreasing 10.46% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 123.87K shares of this stock.
Analyst Rating
Based on
3
analysts
Hold
Current Rating
4.333
Target Price
-0.15%
Upside Space
Quanterix Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Quanterix Corp Info
Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
Ticker SymbolQTRX
CompanyQuanterix Corp
CEOToloue (Masoud)
Websitehttps://www.quanterix.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.40%
+3.76%
+1.10%
+0.28%
-2.09%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Quanterix Corp (QTRX)?
The current price of Quanterix Corp (QTRX) is 4.33.
What is the symbol of Quanterix Corp?
The ticker symbol of Quanterix Corp is QTRX.
What is the 52-week high of Quanterix Corp?
The 52-week high of Quanterix Corp is 8.77.
What is the 52-week low of Quanterix Corp?
The 52-week low of Quanterix Corp is 3.36.
What is the market capitalization of Quanterix Corp?
The market capitalization of Quanterix Corp is 203.77M.
Is Quanterix Corp (QTRX) currently rated as Buy, Hold, or Sell?
According to analysts, Quanterix Corp (QTRX) has an overall rating of signal_hold, with a price target of 4.33.
What is the Earnings Per Share (EPS TTM) of Quanterix Corp (QTRX)?
The Earnings Per Share (EPS TTM) of Quanterix Corp (QTRX) is -2.51.